Form 4: GRI Bio Director Camilla Simpson Granted Stock Options

GRI Bio, Inc. Director Camilla Simpson was granted 5,994 stock options with an exercise price of $1.41, vesting over one year.

Summary

• Camilla V. Simpson, a Director of GRI Bio, Inc. (GRI), was granted 5,994 stock options.
• The options have an exercise price of $1.41 per share.
• The transaction date for the grant was August 26, 2025.
• The options expire on August 26, 2035.
• 4,044 of the options vested immediately upon the grant date.
• The remaining 1,950 options will vest in four equal quarterly installments, becoming fully vested on the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: The filing reports a routine stock option grant to a director, which is a neutral event in terms of immediate company performance or outlook. It reflects standard compensation practices.

Positives

• The grant of stock options aligns the director's interests with long-term shareholder value.
• A portion of the options vested immediately, providing immediate equity exposure.

Future Outlook

NA

Industry Context

Stock option grants to directors are a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation to align leadership interests with company performance and shareholder value. This practice is standard across companies of similar size and stage to GRI Bio, Inc.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice, comparable to those seen at other small-cap biotech firms like Xencor (XNCR) or Zymeworks (ZYME), where equity incentives are crucial for attracting and retaining talent.
• The vesting schedule, with immediate vesting for a portion and quarterly vesting over one year for the remainder, is a common structure for director equity awards, balancing immediate reward with continued commitment.

Related Party Transactions

• The stock option grant to Camilla V. Simpson, a director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, as the options gain value if the stock price increases. It also represents a potential for dilution if options are exercised.
• Employees: No direct impact on general employees is indicated by this specific filing.

Key Dates

Keywords

GRI Bio, GRI, Camilla Simpson, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Beneficial Ownership